Time-to-treatment Discontinuation (TTD) and Real-World Progression-Free Survival (rwpfs) As Endpoints for Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients.
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined